Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 23, 2026Basic & Clinical Pharmacology & Toxicology

Asciminib preserves vascular and endothelial function, supporting a favorable CV safety profile.

View Full Paper
Ask AI
Bookmark
Share

Key result

Asciminib preserves vascular and endothelial function, supporting a favorable cardiovascular safety profile.

Authors

AGAyala Gover‐ProaktorSPShirly PartoucheASAladin Samara

Discussion

Loading...

Member takes

Overview

Should not yet change TKI selection in CML; leaves open clinical CV benefit versus vascular-toxic agents.

Key Points

  • The research aims to evaluate the effects of asciminib on vascular and endothelial function to assess cardiovascular safety.
  • Consultation and data collection on cardiovascular outcomes related to asciminib usage.
  • Analysis of endothelial and vascular function metrics before and after asciminib administration.
  • Asciminib maintains normal vascular function metrics in users.
  • Endothelial performance remains high, supporting cardiovascular safety.

Cite This Study

Gover‐Proaktor et al. (2026) studied this question. Asciminib preserves vascular and endothelial function, supporting a favorable cardiovascular safety profile.

synapsesocial.com/papers/69e9ba6b85696592c86ec96dhttps://doi.org/10.1111/bcpt.70240
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trial2022 · 3 citations
  2. 2OA17 Efficacy and safety of upadacitinib in giant cell arteritis: 2-year results from the re-randomized, double-blind SELECT-giant cell arteritis phase 3 trial2026 · 2 citations
  3. 3P1075Etrasimod for the treatment of Ulcerative Colitis: up to 5 years of safety data from the global clinical programme2026 · 1 citations
  4. 4P178 Long-term safety of upadacitinib across rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis encompassing ∼17,000 patient-years of clinical trial data2026
  5. 5P185 Real-world effectiveness of upadacitinib on early pain control in patients with axial spondyloarthritis: interim results from the UPSTAND observational study2026